A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients

Trial Profile

A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
    • 26 Mar 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top